Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Multi-arm clinical trials use a single control arm to evaluate multiple experimental treatments. In most cases this feature makes multi-arm studies considerably more efficient than two-arm studies. A bottleneck for implementation of a multi-arm trial is the requirement that all experimental treatments have to be available at the enrollment of the first patient. New drugs are rarely at the same stage of development. These limitations motivate our study of statistical methods for adding new experimental arms after a clinical trial has started enrolling patients. We consider both balanced and outcome-adaptive randomization methods for experimental designs that allow investigators to add new arms, discuss their application in a tuberculosis trial, and evaluate the proposed designs using a set of realistic simulation scenarios. Our comparisons include two-arm studies, multi-arm studies, and the proposed class of designs in which new experimental arms are added to the trial at different time points.

[1]  W F Rosenberger,et al.  Bootstrap methods for adaptive designs. , 1999, Statistics in medicine.

[2]  J Jack Lee,et al.  Bayesian adaptive randomization designs for targeted agent development , 2008, Clinical trials.

[3]  J. Wason,et al.  Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? , 2014, Trials.

[4]  Robert K Hills,et al.  Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. , 2011, Blood.

[5]  R. Gray,et al.  Multi-Arm Clinical Trials of New Agents: Some Design Considerations , 2008, Clinical Cancer Research.

[6]  Wenle Zhao,et al.  Flexible Analytical Methods for Adding a Treatment Arm Mid-Study to an Ongoing Clinical Trial , 2012, Journal of biopharmaceutical statistics.

[7]  Lorenzo Trippa,et al.  A Bayesian response-adaptive trial in tuberculosis: The endTB trial , 2017, Clinical trials.

[8]  Nigel Stallard,et al.  To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework , 2019, Statistics in medicine.

[9]  Lorenzo Trippa,et al.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? , 2018, Neuro-oncology.

[10]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[11]  J. Wason,et al.  A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials , 2014, Statistics in medicine.

[12]  Ying Yuan,et al.  MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. , 2016, Statistics in medicine.

[13]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[15]  Lorenzo Trippa,et al.  Bayesian response‐adaptive designs for basket trials , 2017, Biometrics.

[16]  Jeffrey R. Eisele The doubly adaptive biased coin design for sequential clinical trials , 1994 .

[17]  S. Todd,et al.  Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice , 2015, Trials.

[18]  G. Parmigiani,et al.  Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[20]  Feifang Hu,et al.  Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials , 2003 .

[21]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[22]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[23]  Brian P Hobbs,et al.  Controlled multi-arm platform design using predictive probability , 2018, Statistical methods in medical research.

[24]  J. Connor,et al.  The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.